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Abstract: Residual pulmonary impairment is common after treatment for tuberculosis. Lung func-
tion data in patients with HIV-associated tuberculosis are scarce, especially in the context of paradox-
ical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) and prophylactic
prednisone. We aimed to determine the prevalence of lung function abnormalities in patients with HIV-
associated tuberculosis and CD4 counts฀100 cells·฀L<jats:sup>−1</jats:sup> and assess the effect of
prophylactic prednisone and the development of paradoxical TB-IRIS on pulmonary impairment.We per-
formed spirometry, six-minute walk test, and chest radiography at baseline (week 0), week 4, 12, and
28 in participants of the PredART trial, which evaluated a 28-day course of prednisone to prevent TB-
IRIS in patients with HIV-associated tuberculosis commencing antiretroviral therapy.153 participants
underwent spirometry and/or six-minute walk test at one or more time points. Abnormal spirometry
measurements were present in 66% of participants at week 0 and 50% at week 28; low forced vital
capacity was the commonest abnormality. Chest radiographs showed little or no abnormalities in the
majority of participants.Prednisone use resulted in a 42 meters greater six-minute walk distance and a
4.9% higher percentage of predicted forced expiratory volume in 1 s at week 4; these differences were no
longer significantly different from week 12 onwards. TB-IRIS did not significantly impair lung function
outcome.Residual pulmonary impairment is common in HIV-associated tuberculosis. In patients with
low CD4 counts, neither prophylactic prednisone as used in our study nor the development of TB-IRIS
significantly affected week 28 pulmonary outcome.
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“Take home” message: 
Post-tuberculosis lung disease is common in patients with HIV-associated TB at high risk of 
TB-IRIS (CD4 count < 100/μl). Neither TB-IRIS itself, nor prednisone to prevent TB-IRIS 








Residual pulmonary impairment is common after treatment for tuberculosis. Lung function 
data in patients with HIV-associated tuberculosis are scarce, especially in the context of 
paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-
IRIS) and prophylactic prednisone. We aimed to determine the prevalence of lung function 
abnormalities in patients with HIV-associated tuberculosis and CD4 counts ≤ 100 cells/μl and 
assess the effect of prophylactic prednisone and the development of paradoxical TB-IRIS on 
pulmonary impairment. 
 
We performed spirometry, six-minute walk test, and chest radiography at baseline (week 0), 
week 4, 12, and 28 in participants of the PredART trial, which evaluated a 28-day course of 
prednisone to prevent TB-IRIS in patients with HIV-associated tuberculosis commencing 
antiretroviral therapy.  
 
153 participants underwent spirometry and/or six-minute walk test at one or more time 
points. Abnormal spirometry measurements were present in 66% of participants at week 0 
and 50% at week 28; low forced vital capacity was the commonest abnormality. Chest 
radiographs showed little or no abnormalities in the majority of participants. 
Prednisone use resulted in a 42 meters greater six-minute walk distance and a 4.9 % higher 
percentage of predicted forced expiratory volume in 1 second at week 4; these differences 
were no longer significantly different from week 12 onwards. TB-IRIS did not significantly 
impair lung function outcome.  
 
Residual pulmonary impairment is common in HIV-associated tuberculosis. In patients with 
low CD4 counts, neither prophylactic prednisone as used in our study nor the development 






Tuberculosis (TB) is frequently complicated by lung function impairment. The odds of 
abnormal spirometric test results are 2- to 3-fold higher in patients with a history of TB 
compared to those without a history of TB, with both obstructive and/or restrictive 
impairments occuring [1, 2]. Studies of lung function in people with a history of TB found 
abnormal lung function in 45-87% [3-5], with even higher proportions reported in multi-
drug resistant TB [6, 7]. HIV is an independent risk factor for predominantly obstructive lung 
function impairment [8, 9], however data on lung function impairment in HIV-associated TB 
are scarce, as HIV co-infected patients are frequently excluded from studies. TB-related lung 
damage may be less common in those co-infected with HIV, however current data are 
conflicting. (1) A single large study found less pulmonary impairment after TB in patients 
who were HIV positive patients [4], while other studies have not supported this beneficial 
association between HIV status and spirometric outcomes [5, 10, 11]. (2) Further, chest 
radiograph (CXR) findings in patients with HIV-associated TB and low CD4 counts (CD4 < 
200/μl) are frequently normal or atypical [12], (3) and HIV co-infection results in lower levels 
of several of mediators usually implicated in inflammatory lung damage [13]. Conversely, 
paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) after the 
start of antiretroviral therapy (ART) causes inflammation and high levels of inflammatory 
mediators [14-17]. Two recent studies suggest TB-IRIS may cause lung function impairment 
[18, 19], one showing increased inflammation, as assessed by PET-CT scan, was associated 
with worse lung function outcomes [18]. However,  in these cohorts only small numbers of 
patients developed pre-defined TB-IRIS, yet the authors hypothesize that increases in 
pulmonary inflammation can occur as part of not-clinically recognized TB-IRIS. To date, the 
only other study exploring the relationship between TB-IRIS and lung function found worse 
spirometric outcomes in the three patients who developed TB-IRIS compared to eleven 
controls [15].  
 
Corticosteroids reduce inflammation and inhibit several of the immune mediators 
implicated in lung damage during TB [20-23], and may therefore reduce lung function 
impairment associated with TB. Previous studies assessing this association did not find a 
significant effect of corticosteroid use on tests of lung function [24-27]. However, most of 
 
these studies were performed before the introduction of rifampicin, and none included HIV 
co-infected patients.  
 
In this study, we determined the prevalence of lung function impairment over time in a 
randomized controlled trial of patients treated for HIV-associated TB. Additionally, we 
assessed the effect of prednisone evaluated in comparison to placebo for prevention of TB-




Design and setting 
This was a substudy of the PredART trial [28], a randomized, double-blind, placebo-
controlled trial assessing the efficacy of prednisone to prevent TB-IRIS. Participants were 
recruited from Khayelitsha, a peri-urban township in Cape Town, South Africa. They were 
ambulant and treated in an outpatient setting. They received either prednisone or placebo 
(40 mg/day for 2 weeks, followed by 20 mg/day for 2 weeks), starting within 48 hours after 
starting ART. Study drug could be replaced with open-label prednisone (1.5 mg/kg/day for 2 
weeks, followed by 0.75 mg/kg/day for 2 weeks or longer if clinically indicated) for 
treatment of TB-IRIS. TB-IRIS events were adjudicated by three clinical experts using the 
International Network for the Study of HIV-associated IRIS (INSHI) consensus case definition 
[29]. 
Enrolment for the substudy started later than the main trial. Participants already enrolled in 
the main trial could enrol in the substudy from their next eligible visit, if they had not 
completed the main trial yet. Participants treated for multi-drug resistant TB or who 
prematurely discontinued TB treatment were excluded from the analysis at week 28. 
Successful completion of TB treatment was defined following South African National 
Tuberculosis Management Guidelines [30]. 
The substudy was approved by the same ethical committees that approved the main trial 




Substudy visits were scheduled at week 0 (initiation of ART and study drug), 4, 12, and 28. 
At each visit, pulmonary symptoms (cough, dyspnoea at exertion, and dyspnoea at rest) 
were assessed by the trial doctor and spirometry and six-minute walk test (6MWT) were 
performed. Forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) 
were measured using a desktop spirometer (MIR Spirolab III, Roma, Italy). Tests were 
performed and results interpreted using the 2005 American Thoracic Society / European 
Respiratory Society guidelines for spirometry, using NHANES reference ranges [31]. We 
defined four possible outcomes (Figure S1): normal lung function (FEV1/FVC  70% and FVC 
 80% of the predicted value), low FVC (FEV1/FVC  70% and FVC < 80% of the predicted 
value), obstructive impairment with and without low FVC (FEV1/FVC < 70% of the predicted 
value), and ‘technically incorrect’, consisting of participants who performed spirometry but 
did not meet criteria for interpretation (Table S1). 6MWTs were performed following the 
2002 American Thoracic Society guidelines [32] on a 20-meter outdoor track. CXRs were 
performed at week 0 and 28. After completion of the study, digitized CXRs were scored by 
two independent blinded readers, using an adapted version of the Timika score as described 
by Kriel et al [33]. Where discrepancy existed, defined as a difference in score of more than 
10 points, a third reader evaluated the CXR and consensus was found using a 2-1 vote. 
 
Statistical methods 
Analyses were performed using Stata 15.1. For categorical variables the proportions and for 
continuous variables the medians with interquartile ranges (IQR) were estimated at 
different time points. Comparison of the Karnofsky Performance Score (KPS) between 
groups was done using a mixed effects proportional odds model. Correlation between CXR 
score and lung function was done using mixed effects regression (linear or logistic) models. 
Mixed effect models including a random intercept and covariates were used to model the 
evolution of pulmonary function over time. The effect of prophylactic prednisone on 
pulmonary function was tested using a test of the interaction of prednisone and visit 
number; participants receiving prednisone as treatment for TB-IRIS were analysed in their 
intention-to-treat arm (ie. study placebo or prednisone). The effect of TB-IRIS was tested 
 
using a joint test of the main effect of TB-IRIS and its interaction with visit number. A p-




Between January 2015 and February 2016, 153 participants were enrolled, 77 from the 
prednisone arm and 76 from the placebo arm. The flow of participants is described in Figure 
1; baseline characteristics are summarized in Table 1. Seventy-one participants (46%) 
developed TB-IRIS, 30 in the prednisone and 41 in the placebo arm; 46 (30%) participants 
received open-label prednisone as treatment for TB-IRIS, 16 in the prednisone and 30 in the 
placebo arm.  
 
Overall prevalence of lung function abnormalities 
Symptoms 
Eighty percent of participants reported cough, dyspnoea on exertion, and/or dyspnoea at 
rest as one of their presenting TB symptoms.  At week 0, a median of 16 (IQR 15-21) days 
into TB treatment, 50% had one or more of these symptoms. Symptoms improved over 
time; however, 8% of participants who successfully completed their TB treatment at week 
28 still had one or more respiratory symptom (Table 2). 
 
Spirometry 
A total of 426 spirometry tests were performed. In 15 substudy participants, spirometry was 
not performed at one or more time points; 5 of these participants were too ill to perform 
spirometry, the remaining 10 were not done for logistic reasons.  Spirometic outcomes at 
different time points are shown in Table 2. The proportion of participants with a normal 
spirometry outcome was 26.4% at week 0, increasing to 47.4% at week 28. Low FVC was the 
commonest abnormality. The proportion of participants with obstruction with or without 
low FVC was low and roughly the same over time. We found no effect of CD4 cell count 
recovery on change over time of spirometric outcomes (p = 0.71 for FEV1). 
At week 0, 23 (21.7%) participants performed a technically incorrect test; the main reason 
was the inability to exhale for 6 seconds. To assess if this possibly reflected more impaired 
 
lung function, we compared six-minute walking distance (6MWD) and KPS between 
participants with correctly and incorrectly performed tests. On average, the participants 
with an incorrect test had a 6MWD which was 56 meters (95% CI 30-83; p < 0.001) shorter 
and a lower KPS (p < 0.001). At week 12, 13 out of 20 participants with an initial incorrect 
test had obstruction and/or a low FVC; with similar findings in 11 out of 16 participants at 
week 28.  
 
Six-minute walking distance 
A total of 410 6MWTs were performed; 29 substudy participants did not perform a walking 
test at one or more time points, main reasons being painful feet or rain. Median 6MWD was 
520 meters (IQR 465-576) at week 0 and 585 meters (IQR  520-655) at week 28 (Table 2).  
 
Chest radiograph score 
CXR scores were available for 135 participants at week 0, and for 61 participants at week 28. 
Possible scores ranged from 0 to 140, with higher scores indicating more CXR abnormalities. 
The median CXR scores were low: 4.0 (IQR 0.8-11.7) at week 0, and 0.9 (IQR 0-3.75) at week 
28 (Table 2). Cavities were present in 8 (6%) participants at week 0 and 1 (2%) participant at 
week 28. Overall, CXR scores showed significant correlation with respiratory symptoms, 
6MWD and FEV1: for an increase of 10 points in CXR score, an OR of 1.51 for symptoms 
(95% CI 1.13-2.03; p = 0.006) was observed (Table S2); the average 6MWD decreased by 21 
meters (95% CI 11-31; p < 0.001); and the average FEV1 percentage of predicted decreased 
by 3.3 % (95% CI 1.9-4.8; p<0.001). However, in CXRs with lower scores (i.e. below 10), the 
FEV1 varied markedly, and both normal and impaired lung function were seen in 
participants with little or no CXR abnormalities (Figure S2). 
There was no significant association between CXR score at week 0 and spirometry results at 
week 28 (OR for normal lung function at week 28 per 10 points increase in CXR score at 
week 0 was 0.77 (95% CI 0.55-1.08; p = 0.13); and average FEV1 percentage of predicted at 
week 28 was 1.87% lower (95% CI 3.98 - -0.24; p = 0.08) for every 10-point increase of week 
0 CXR score). 
 
 
Effect of prednisone 
There was no statistically significant difference in the change over time of symptoms 
(p=0.13) or CXR score (p=0.92) between the prednisone and the placebo arm. The change in 
6MWD over time was statistically significantly different between the groups (p=0.03), with 
the largest difference at week 4: participants in the prednisone arm walked 42 (95% CI 13-
72) meters further compared to participants in the placebo arm. Change over time of both 
FEV1 and FVC were also statistically significantly different between the two arms (p = 0.03 
and p = 0.01), once again most obvious at week 4, with those in the prednisone arm having 
a FEV1 percentage of predicted that was 4.9% (95% CI 0.7-9.0%) higher and a FVC 
percentage of predicted that was 4.9% (95% CI1.3-8.5%) higher at week 4 compared to 
those in the placebo arm. Adjusting for the use of prednisone as treatment for TB-IRIS gave 
similar results (Table S3). Baseline lung function did not statistically significantly affect the 
impact of prednisone (p = 0. 56 for FEV1) (Table S4). At week 28, there was no longer a clear 
difference in either the 6MWD or FEV1 and FVC between the arms (Figure 2 and Tables 3 
and S5).  
  
Effect of TB-IRIS 
When comparing participants who developed paradoxical TB-IRIS to those who did not, TB-
IRIS was associated with a change in the presence of symptoms over time (p = 0.03), but 
there was no statistically significant difference in change over time of FEV1 percentage of 
predicted (p = 0.11), FVC percentage of predicted (p  = 0.054), 6MWD (p = 0.62), or CXR 
score (p = 0.20) (Figure 3 and Tables 4 and S6).  
Sixteen participants developed TB-IRIS without any respiratory signs or symptoms. Exclusion 





We assessed pulmonary function in a cohort of patients with HIV-associated TB at high risk 
for TB-IRIS, enrolled in a trial investigating the efficacy of prophylactic prednisone in 
preventing TB-IRIS.  
 
 
Respiratory symptoms were common early during TB treatment and abnormal spirometry 
(low FVC and airflow obstruction with and without low FVC) was found in 66% of 
participants with acceptable spirometry. At the end of TB treatment, symptoms persisted in 
8% and abnormal spirometry in 50% of participants. The proportion of abnormal spirometry 
results is higher than expected for either the general or HIV-infected population [1, 34], but 
is comparable to results from other studies in HIV-associated TB patients [4, 5, 19].  
 
In our trial, open-label treatment of TB-IRIS with prednisone was allowed. This resulted in 
30/76 participants in the placebo arm receiving prednisone for the treatment of TB-IRIS and 
the majority of the participants who developed TB-IRIS receiving prednisone, either as 
prophylaxis, as treatment, or both, with prednisone treatment given to the more severe 
cases of TB-IRIS. This limits our evaluation of the individual effects of both prednisone as 
well as TB-IRIS on lung function.  
  
Within these limitations, we did not find an effect of TB-IRIS on spirometric lung function 
over time. This contradicts findings of two recent studies [18, 19] that hypothesized that TB-
IRIS-like increases in inflammation may lead to decreased lung function, which may occur  in 
patients with HIV-associated TB initiating ART, even in the absence of clinically overt TB-IRIS. 
It is possible that in the present study, mild TB-IRIS did not result in sufficient additional 
pulmonary inflammation to affect long-term respiratory outcomes, whereas in severe TB-
IRIS the effect was ameliorated by treatment with prednisone.  
 
We found prophylactic prednisone affected change over time of both 6MWD and FEV1 and 
FVC, primarily at week 4, when participants completed their study prednisone, potentially 
by preventing TB-IRIS. Consequently, the higher proportion of participants with TB-IRIS in 
the placebo arm may be responsible for the demonstrated favourable effect of prophylactic 
prednisone on lung function. Additionally, prednisone can directly improve exercise 
performance [36] and FEV1 in other disease processes, for example acute exacerbations of 
chronic obstructive pulmonary disease (COPD) [37]. Ravimohan et al [18] found that 
decreased lung function after 4 weeks of TB treatment, impacts negatively on long-term 
lung function, and Auld et al [19] found similar associations, but only in severe lung function 
 
declines. In the current study, despite an increase in lung function at week 4, we did not 
observe any long-term effects of prophylactic prednisone on lung function. This could be 
due to type 2 error, with large proportion of participants in the placebo arm receiving 
prednisone as treatment for TB-IRIS. Alternatively, prednisone may have been given too late 
in the disease process and prescribed only after lung damage had already occurred.  
 
We found a high proportion of participants with technically incorrect spirometry results 
early on during treatment – a finding not reported previously. In studies performed  in 
participants without TB, in the latter stages of TB treatment or after TB treatment, 2-30% 
did not perform spirometry correctly and these patients were subsequently excluded [1, 3-
5, 9, 18, 38]. We considered that the participants who did not perform spirometry correctly 
might include those with worse pulmonary status: for example, in severely ill patients, and 
in those with significant cough and/or shortness of breath spirometry is technically 
challenging. This hypothesis was supported in our study by finding that the majority of 
technically incorrect spirometric results were due to inability of patients to exhale for six 
seconds. Further, the association with a shorter 6MWD and a lower KPS, and abnormal lung 
function in the majority of these participants at follow-up spirometry testing adds weight to 
this argument. Thus, excluding these participants from the analyses may underestimate the 
burden of lung function impairment in TB. In our study, when technically incorrect were 
included as abnormal, the percentage abnormal tests at baseline increased from 66% to 
74%. 
 
In keeping with published data on HIV-associated TB patients with a low-CD4 count  [12], 
only a small proportion of participants demonstrated extensive CXR abnormalities, while 
cavitation was uncommon. Our finding of a negative association between CXR score and 
FEV1, although statistically significant, needs to be interpreted with caution. Although a high 
score is unsurprisingly associated with lower FEV1, a low score does not appear to rule out 
significant abnormality in FEV1.  Several other studies, using many different scoring 
methods, have reported the relationship between FEV1 and CXR score in TB [3, 5, 10, 39, 
40]. However, all studies describe more severe CXR abnormalities than our present study, 
and few included HIV positive patients. Those that did, chose not to report data on HIV 
patients specifically, or claimed the numbers were too small for meaningful sub-analysis. 
 
Our observation that the presence of a normal CXR in HIV-associated TB patients with a CD4 
count < 100 cells/μl does not exclude lung function abnormalities, is likely explained by the 
insensitivity of CXR to detect changes responsible for the reduced FEV1, for example small 
airways and subtle parenchymal abnormalities.  
 
Besides the considerable overlap between participants developing TB-IRIS and participants 
prescribed prednisone to treat TB-IRIS, our study has other limitations. First, as 
consequence of the substudy commencing after the main trial, we do not have complete 
data on all participants. Second, we do not have reliable information about the time 
between the start of symptoms and the start of TB treatment, with longer duration of 
symptoms being a risk factor for pulmonary impairment [5, 41]. Third, normal values for 
6MWD in our population are lacking. Most participants walked relatively far, possibly 
because of the relatively short duration of illness and possibly younger age of participants 
when compared with other chronic lung diseases. Finally, the use of the NHANES reference 
range (derived in North American populations) may have resulted in an overestimate of lung 
function impairment, as normal values for FEV1 and FVC tend to be higher than those for 
African populations [35]. 
 
In conclusion, we found that lung function impairment is common in patients with HIV-
associated TB. Prednisone to prevent TB-IRIS improved lung function at week 4, possibly by 
reducing TB-IRIS, however, the 28-day course of prednisone did not improve lung function 
from week 12 onwards in patients with CD4 counts < 100 cells /μl. Overlap between the 
groups through the development of TB-IRIS and subsequent use of prednisone as 
treatment, limits our ability to make definitive conclusions. Prednisone remains 
recommended to prevent TB-IRIS in this population based on the findings of the main 
PredART trial [28], despite this study being unable to demonstrate long term benefits in lung 
function. Further studies, using PET-CT imaging and other biomarkers of inflammation and 
lung damage in TB [13] are needed to better understand the pathogenesis of lung function 
impairment in HIV-associated TB.  
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TABLE 1 Baseline characteristics and participants developing TB-IRIS and receiving prednisone as 
treatment according to trial arm 
   
 Prednisone Placebo 
   
Male 49 (64%) 41 (54%) 
Age (years) 38 (31-43) 38 (31-44) 
CD4 count (cells/μl) 46 (24-81) 50 (24-86) 
HIV viral load (log10 copies/ml) 5.5 (5.2-5.8) 5.6 (5.3-5.9) 
Extra-pulmonary TB (N=123) 24 (38%) 33 (55%) 
Microbiologically confirmed TB 53 (70%) 59 (79%) 
Previous TB  6 (8%) 8 (11%) 
Time on TB treatment at week 0 (days) 16 (15-22) 16 (14-21) 
Smoking status at week 0 / py (N=127)   
     Never smoked 36 (55%) 41 (67%) 
     Ever smoked 30 (45%) / 2.2 (0.8-5.0) 20 (33%) / 3.75 (1.0-10.0) 
Previous lung disease 1 (1.3%) 0 (0%) 
Spirometry    
     FEV1 (% of predicted) 75 (61-88) 73 (59-86) 
     FVC (% of predicted) 74 (66-89) 73 (65-81) 
     FVC/FEV1 (%) 83 (79-85) 82 (77-86) 
TB-IRIS 30 (39%) 41 (54%) 
Treatment with open-label prednisone for 
suspected TB-IRIS 
16 (21%) 30 (39%) 
   
TB = tuberculosis, pulmonary tuberculosis = participants with one or more pulmonary signs or symptoms (such as cough, shortness of 
breath, abnormal chest radiographs) of tuberculosis at presentation, extrapulmonary tuberculosis = participants with signs of  
extrapulmonary tuberculosis (such as pleural effusion or enlarged lymph nodes), microbiologically confirmed TB = participants with 
Mycobacterium tuberculosis detected on culture, with the use of the Xpert MTB/RIF assay (Cepheid), or as positive acid-fast bacilli on 










TABLE 2 Symptoms, spirometric outcomes, 6MWD and CXR score in the whole study group at different time points 
     
 week 0 week 4 week 12 week 28 
     
Symptoms (N) 107 99 110 111 
     cough  40 (37.4%) 29 (29.3%) 14 (12.7%) 5 (4.5%) 
     dyspnoea at exertion 37 (34.6%) 27 (27.3%) 12 (10.9%) 5 (4.5%) 
     dyspnoea at rest 11 (10.3%) 8 (8.1%) 3 (2.7%) 1 (0.9%) 
     total 54 (50.5%) 43 (43.4 %)  20 (18.2%) 9 (8.1%) 
         
Spirometry outcome (N) 106 96 110 114 
     normal 28 (26.4%) 36 (37.5%)   50 (45.5%) 54 (47.4%) 
     low FVC 48 (45.3%) 42 (43.8%)   43 (39.1%) 44 (38.6%) 
     obstruction +/- low FVC 7 (6.6%) 7 (7.3%)   10 (9.1%) 11 (9.7%) 
     technically incorrect  23 (21.7%) 11 (11.5%)   7 (6.4%) 5 (4.4%) 
         
6MWD (N) 102 91 104 113 
 520 (465-576) 524 (450-579) 539 (483-608) 585 (520-655) 
         
CXR score (N) 135     61 
 4 (0.8-11.7)     0.9 (0-3.75) 
         
N = total number of participants per test per visit; Symptoms total = cough, and/or dyspnea at exertion, and/or dyspnea at rest; normal = 
FEV1/FVC  70% and FVC  80% of the predicted value; low FVC = FEV1/FVC  70% and FVC < 80% of the predicted value; obstruction +/- low FVC 
= FEV1/FVC < 70%; technically incorrect = test not fulfilling criteria for interpretation; 6MWD = six-minute walk distance in meters; CXR = chest X-
ray; week 0 = the start day of anti-retroviral therapy and prednisone/placebo (median 16 days after start of antituberculosis treatment). Data are 
shown as number (percentage) or median (interquartile range). 
 
 
TABLE 3 The effect of prednisone prophylaxis on change over time of pulmonary function parameters 
 
Change over time of six-minute walking distance (6MWD) in meters 
    
 6MWD  95% CI  
Intercept     
(average 6MWD at week 0 for non-smokers) 504 484 – 523  
    
 Mean change in 6MWD   95% CI p-value 
Effect of smoking (ever vs never) 14 -11 – 39 0.275 
    
 Mean change in 6MWD 
from week 0 95% CI p-value 
Effect of time (visit)   <0.0001 
      week 4 -27  -50 – -3  
      week 12 32  10 – 54  
      week 28 64  42 – 86  
Effect of prophylactic prednisone    0.034 
      week 4 42  13 – 72  
      week 12 2  -26 – 30  
      week 28 13  -15 – 41  
    
    
Change over time of forced expiratory volume in 1 second (FEV1) as % of predicted value 
    
 FEV1 % 95% CI  
Intercept    
(average FEV1 % at week 0 for non-smokers) 76.9 73.6 – 80.2  
    
 Mean change in FEV1 %   95% CI p-value 
Effect of smoking (ever vs never) -4.7 -8.8 – -0.5 0.027 
    
 Mean change in FEV1 % 
from week 0 95% CI p-value 
Effect of time (visit)  
  
<0.0001 
      week 4 -1.1 -4.4 – 2.1  
      week 12 3.3 0.2 – 6.4  
      week 28 6.8 3.6 – 10.0  
Effect of prophylactic prednisone    0.029 
      week 4 4.9 0.7 – 9.0  
      week 12 -0.4 -4.4 – 3.5  
      week 28 -1.5 -5.6 – 2.6  
    
Intercept and estimated coefficients with their 95% confidence intervals (95% CI) from the mixed effects regression models ar e listed. 
Data are adjusted for all other covariates presented in the table. Effect of time (visit) refers to the effect of time in the placebo arm.  
Because allocation to either the prednisone or the placebo arm was randomized, no adjustment for baseline variables  other than 





TABLE 4 The effect of tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) on 
change over time of pulmonary function parameters 
    
Change over time of six-minute walking distance (6MWD) in meters 
    
 6MWD 95% CI p-value 
Intercept     
(average 6MWD if all other co-variates are 0) 837 711-964  
    
 Mean change in 
6MWD  95% CI p-value 
    
Effect of TB-IRIS at week 0 -4 -35 - 27 0.79 
Effect of smoking (ever vs never) -44 -69 – -19 0.001 
Effect of age (per increase of one year in age at week 0) -3 -4 – -2 <0.001 
Effect of gender (female vs male) -112 -138 – -86 <0.001 
Effect of type of TB (participants without signs of 
extrapulmonary TB vs those with signs of extrapulmonary TB) 30 -14 – 74 0.19 
Effect of HIV viral load (per log10 cps/ml increase at screening) -32 -50 - -13 0.001 
Effect of CD4 count (per increase of 10 CD4 cells/μl at 
screening) -2 -4 – 1 0.21 
Effect of previous tuberculosis -21 -60 – 18 0.28 
    
 Mean change in 
6MWD from 
week 0 95% CI p-value 
    
Effect of time (visit)    <0.0001 
      week 4 -16 -45 – 14  
      week 12 40 13 – 67  
      week 28 72 44 – 100  
Effect of TB-IRIS    0.68 
      week 4 -21 -54 – 13  
      week 12 -11 -44 – 21  
      week 28 -7 -40 – 27  
Effect of prophylactic prednisone   0.036 
      week 4 41 13 – 70  
      week 12 0 -27 – 26  
      week 28 4 -22 – 31  
    
    
Change over time of forced expiratory volume in 1 second (FEV1) as % of predicted value 
    
 FEV1 % 95% CI p-value 
Intercept    
(average FEV1 % if all other co-variates are 0) 83.9 57.5-110.3  
    
 Mean change in 
FEV1 % 95% CI p-value 
    
Effect of TB-IRIS at week 0 3.2 -2.7 – 9.2 0.29 
Effect of smoking (ever vs never) -5.9 -10.6 – -1.1 0.02 
Effect of age (per increase of one year in age at week 0) 0.04 -0.2 – 0.3 0.76 
Effect of gender (female vs male) -3.6 -9.0 – 1.8 0.19 
Effect of type of TB (participants without signs of 
extrapulmonary TB vs those with signs of extrapulmonary TB) 0.7 -8.6 – 10.1 0.88 
 
Effect of HIV viral load (per log10 cps/ml increase at screening) -0.5 -4.5 – 3.4 0.79 
Effect of CD4 count (per increase of 10 CD4 cells/μl at 
screening) -0.8 -1.3 – -0.2 0.005 
Effect of previous tuberculosis -14.8 -23.4 – -6.1 0.001 
    
 Mean change in 
FEV1 % from 
week 0 95% CI p-value 
    
Effect of time (visit)    <0.001 
      week 4 1.4 -3.0 – 5.7  
      week 12 6.3 2.3 – 10.4  
      week 28 8.1 3.9 – 12.3  
Effect of TB-IRIS   0.06 
      week 4 -4.7 -9.4 – -0.1  
      week 12 -6.0 -10.5 – -1.4  
      week 28 -2.8 -7.6 – 2.0  
Effect of prophylactic prednisone   0.07 
      week 4 4.4 0.2 – 8.7  
      week 12 -0.1 -4.8– 3.2  
      week 28 -1.3 -5.5 – 2.8  
 
Intercept and estimated coefficients with their 95% confidence intervals (95% CI) from the mixed effects regression models ar e listed. 






















Figure 2 The effect of prednisone prophylaxis to prevent TB-IRIS on lung function. Patients 
treated for HIV-associated TB received either prednisone (in blue) or identical placebo (in 
black) during the first 4 weeks of antiretroviral therapy. Week 0 is the day when 
antiretroviral therapy and prednisone or placebo were started. (A) Change over time of six-
minute walk distance was statistically significantly associated with prednisone use (p = 
0.034). (B) Change over time of FEV1 and FVC percentage of predicted was statistically 
significantly associated with prednisone use (p=0.029 & p=0.015, respectively). Graphs 









Figure 3 The effect of the development of tuberculosis-associated immune reconstitution 
inflammatory syndrome (TB-IRIS) on lung function. Patients with TB-IRIS (blue) are 
compared to those without TB-IRIS (black). (A) Change over time of six-minute walk distance 
was not statistically significantly associated with TB-IRIS (p = 0.62). (B) Change over time of 
FEV1 and FVC percentage of predicted was not statistically significantly associated with TB-
IRIS (p = 0.11 & p = 0.054, respectively)). Graphs represent data for male non-smokers in the 
placebo arm of age 40 who have pulmonary TB, an HIV viral load at screening of 800000 
copies/ml, a CD4 at screening of 100 cells/μl and did not have previous TB. The difference 
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Figure S2 The association between chest X-ray score and FEV1 percentage of predicted  
(n = 135). Chest X-rays were scored using an adapted version of the Timika score
1)
: visible lung fields on the 
chest X-ray were divided into six zones and the percentage of affected lung in each zone and its prominent 
opacification type were estimated. A total score was generated by adding up the percentages of each zone and 
dividing the total by the number of scored zones (usually 6), adding an additional 40 points if one or more 
cavities > 1cm in diameter were present. Therefore, total scores could range from 0 to 140. Chest X-ray scores 
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TABLE S1 Acceptability criteria for the recording of FVC and FEV1 using spirometry 
  
No artefacts Coughing during first second of expiration 
 Glottis closure  
 Early termination or submaximal effort 
 Leak 
 Obstructed mouthpiece 
Good starts Extrapolated volume < 5% of FVC or 0,15l, whichever is greater 
Exhalation Duration  6 s, plateau in the volume-time curve, or if the subject cannot or 
should not continue 
  
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jen sen R, 
Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, Force AET. Standardisation of spirometry. 








TABLE S2 Association between chest X-ray score and respiratory symptoms 
   
 Odds ratio  p-value 
Cough 1.24 0.08 
Dyspnoea at exertion 1.45 0.007 
Dyspnoea at rest 1.03 0.89 
Total 1.51 0.006 
Total = cough, and/or dyspnea at exertion, and/or dyspnea at rest. Odds ratio’s are calculated for an increase of 10 units in chest-X-ray 




TABLE S3 The effect of prednisone prophylaxis on change over time of pulmonary function parameters, 
adjusted for prednisone as treatment 
    
Change over time of six-minute walking distance (6MWD) in meters 
    
 6MWD 95% CI p-value 
Intercept     
(average 6MWD if all other co-variates are 0) 662 595 – 729  
    
 Mean change in 
6MWD  95% CI p-value 
    
Effect of prednisone as treatment -20 -44 - 4 0.097 
Effect of smoking (ever vs never) -45 -70 - -20 <0.001 
Effect of age (per increase of one year in age at week 0) -3 -4 – -1 <0.001 
Effect of gender (female vs male) -108 -133 – -82  <0.001 
Effect of type of TB (participants without signs of 
extrapulmonary TB vs those with signs of extrapulmonary 
TB) 
35 -9 – 78 0.12 
Effect of HIV viral load (per log10 cps/ml increase at 
screening) 
-1 -2 – -1  <0.001 
Effect of CD4 count (per increase of 10 CD4 cells/μl at 
screening) 
-1 -3 – 2 0.48 
Effect of previous tuberculosis -26 -64 – 13 0.19 
    
 Mean change in 
6MWD from 
week 0 95% CI p-value 
    
Effect of time (visit)    <0.0001 
      week 4 -27 -50 – -4   
      week 12 34 13 – 56  
      week 28 69 48 – 91  
Effect of prophylactic prednisone   0.020 
      week 4 44 15 – 72  
      week 12 -0.03 -27 – 27  
      week 28 3 -23 – 30  
    
    
Change over time of forced expiratory volume in 1 second (FEV1) as % of predicted value 
    
 FEV1 % 95% CI p-value 
Intercept    
(average FEV1 % if all other co-variates are 0) 80.7 65.9 – 95.5  
    
 Mean change in 
FEV1 % 95% CI p-value 
    
Effect of prednisone as treatment 1.5 -3.7 – 6.8 0.57 
Effect of smoking (ever vs never) -5.6 -10.3 - -0.8 0.022 
Effect of age (per increase of one year in age at week 0) 0.06 -0.2 – 0.3 0.66 
Effect of gender (female vs male) -3.5 -8.8 – 1.9 0.21 
Effect of type of TB (participants without signs of 
extrapulmonary TB vs those with signs of extrapulmonary 
TB) 
0.7 -8.6 – 10.1 0.88 




Effect of CD4 count (per increase of 10 CD4 cells/μl at 
screening) 
-0.7 -1.3 – -0.2 0.008 
Effect of previous tuberculosis -14.8 -23.4 – -6.2 0.001 
    
 Mean change in 
FEV1 % from 
week 0 95% CI p-value 
    
Effect of time (visit)    <0.0001 
      week 4 -1.5 -4.8 – 1.8  
      week 12 2.9 -0.3 – 6.1  
      week 28 6.4 3.1 – 9.6  
Effect of prophylactic prednisone   0.043 
      week 4 5.1 0.9 – 9.4  
      week 12 -0.04 -4.1 – 4.0  
      week 28 -1.0 -5.1 – 3.2  
 
Intercept and estimated coefficients with their 95% confidence intervals (95% CI) from the mixed effects 
regression models are listed. Data are adjusted for all other covariates presented in the table. We have not 






TABLE S4 The effect of baseline spirometry outcome on the effect of prednisone on change over time of 
forced expiratory volume in 1 second (FEV1) as % of predicted value 
 
 FEV1 % 95% CI  
Intercept    
(average FEV1 % at week 0 for non-smokers 
with abnormal spirometry result) 67.1 63.4 - 70.8 <0.001 
    
 Mean change in FEV1 %   95% CI p-value 
Effect of spirometry outcome at baseline 
(normal vs abnormal) 25.6 20.2 - 31.0 <0.001 
Effect of smoking (ever vs never) -2.0 -6.0 – 2.0 0.33 
    
 Mean change in FEV1 % 
from week 0 95% CI p-value 
Effect of time (visit)    <0.0001 
      week 4 -0.3 -4.5 – 3.8  
      week 12 4.3 0.4 – 8.2  
      week 28 9.8 5.6 – 14.0  
Effect of prophylactic prednisone    0.12 
      week 4 5.9 0.7 – 11.2  
      week 12 0.8 -4.5 – 6.0  
      week 28 -0.4 -6.1 – 5.3  
Effect of normal spirometry at baseline   0.41 
      week 4 -0.4 -7.6 – 6.7  
      week 12 -3.0 -10.5 – 4.5  
      week 28 -6.7 -15.0 – 1.6  
Effect of normal spirometry at baseline on 
the effect of prophylactic prednisone 
  0.56 
      week 4 -5.3 -14.2 – 3.6  
      week 12 -5.7 -15.0 – 3.7  
      week 28 -3.3 -13.6 – 7.1  
    
Intercept and estimated coefficients with their 95% confidence intervals (95% CI) from the mixed effects regression models are listed. 
Data are adjusted for all other covariates presented in the table. Because allocation to either the prednisone or the placebo arm was 
randomized, no adjustment for baseline variables other than smoking and baseline spirometry outcome was done. Only participants 







TABLE S5 The effect of prednisone prophylaxis on change over time of forced vital capacity (FVC) as % of 
predicted value 
 
 FVC % 95% CI  
Intercept    
(average FVC % at week 0 for non-smokers) 77.3 74.4 – 80.3  
    
 Mean change in FVC %   95% CI p-value 
Effect of smoking (ever vs never) -5.0 -8.7 – -1.2 0.009 
    
 Mean change in FVC % 
from week 0 95% CI p-value 
Effect of time (visit)    <0.0001 
      week 4 -0.8 -3.7 – 2.0  
      week 12 4.3 1.6 – 7.0  
      week 28 7.3 4.5 – 10.1  
Effect of prophylactic prednisone    0.015 
      week 4 4.9 1.3 – 8.5  
      week 12 -0.1 -3.5 – 3.4  
      week 28 -0.8 -4.4 –2.7  
Intercept and estimated coefficients with their 95% confidence intervals (95% CI) from the mixed effects regression models are listed. 





TABLE S6 The effect of tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) on 
change over time of forced vital capacity (FVC) as % of predicted value 
    
 FVC % 95% CI p-value 
Intercept    
(average FVC % if all other co-variates are 0) 80.3 55.7 – 104.8 <0.001 
    
 Mean change in 
FVC % 95% CI p-value 
    
Effect of TB-IRIS at week 0 2.9 -2.6 – 8.3 0.30 
Effect of smoking (ever vs never) -5.9 -10.1 – -1.6 0.007 
Effect of age (per increase of one year in age at week 0) 0.1 -0.2 – 0.4 0.45 
Effect of gender (female vs male) -2.7 -7.8 – 2.3 0.29 
Effect of type of TB (participants without signs of 
extrapulmonary TB vs those with signs of extrapulmonary 
TB) 3.7 -5.0 – 12.5 0.40 
Effect of HIV viral load (per log10 cps/ml increase at 
screening) -1.0 -4.6 – 2.7 0.61 
Effect of CD4 count (per increase of 10 CD4 cells/μl at 
screening) -0.7 -1.2 – -0.2 0.009 
Effect of previous tuberculosis -10.6 -18.7 – -2.6 0.010 
    
 Mean change in 
FVC % from 
week 0 95% CI p-value 
    
Effect of time (visit)    <0.0001 
      week 4 1.7 -2.0 – 5.5  
      week 12 7.5 3.9 – 11.0  
      week 28 8.7 5.0 – 12.3  
Effect of TB-IRIS   0.026 
      week 4 -4.4 -8.5 – -0.4  
      week 12 -5.7 -9.7 – -1.8  
      week 28 -2.5 -6.7 – 1.7  
Effect of prophylactic prednisone   0.040 
      week 4 4.5 0.7 – 8.2  
      week 12 -0.4 -4.0 – 3.1  
      week 28 -0.8 -4.4 – 2.9  
Intercept and estimated coefficients with their 95% confidence intervals (95% CI) from the mixed effects regression models ar e listed. 
Data are adjusted for all other covariates presented in the table 
 
